Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

80 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Abiraterone acetate versus docetaxel for metastatic castration-resistant prostate cancer: a cohort study within the French nationwide claims database.
Thurin NH, Rouyer M, Jové J, Gross-Goupil M, Haaser T, Rébillard X, Soulié M, de Pouvourville G, Capone C, Bazil ML, Messaoudi F, Lamarque S, Bignon E, Droz-Perroteau C, Moore N, Blin P. Thurin NH, et al. Among authors: rouyer m. Expert Rev Clin Pharmacol. 2022 Sep;15(9):1139-1145. doi: 10.1080/17512433.2022.2115356. Epub 2022 Aug 25. Expert Rev Clin Pharmacol. 2022. PMID: 35984212
Real-life patterns of use and effectiveness of bortezomib: the VESUVE cohort study.
Fourrier-Réglat A, Noize P, Facon T, Fermand JP, Fitoussi O, Marit G, Thomaré P, Robinson P, Bignon E, Jové J, Lassalle R, Rouyer M, Grelaud A, Moore N; VESUVE Study Group. Fourrier-Réglat A, et al. Among authors: rouyer m. Leuk Lymphoma. 2014 Apr;55(4):848-54. doi: 10.3109/10428194.2013.806801. Epub 2013 Aug 28. Leuk Lymphoma. 2014. PMID: 23808815
Secondary Metastases Resection After Bevacizumab Plus Irinotecan-Based Chemotherapy in First-Line Therapy of Metastatic Colorectal Cancer in a Real-Life Setting: Results of the ETNA Cohort.
Rouyer M, Smith D, Laurent C, Becouarn Y, Guimbaud R, Michel P, Tubiana-Mathieu N, Balestra A, Jové J, Robinson P, Noize P, Moore N, Ravaud A, Fourrier-Réglat A; ETNA study group. Rouyer M, et al. Target Oncol. 2016 Feb;11(1):83-92. doi: 10.1007/s11523-015-0377-6. Target Oncol. 2016. PMID: 26298481
Patterns and effectiveness of bortezomib use according to age in the VESUVE cohort.
Grelaud A, Fourrier-Réglat A, Fitoussi O, Facon T, Jové J, Bénichou J, Robinson P, Marit G, Rouyer M, Moore N, Noize P; VESUVE Study Group. Grelaud A, et al. Among authors: rouyer m. Leuk Lymphoma. 2016;57(6):1349-54. doi: 10.3109/10428194.2015.1096354. Epub 2015 Nov 16. Leuk Lymphoma. 2016. PMID: 26397802
Real-life patterns of use, safety and effectiveness of sunitinib in first-line therapy of metastatic renal cell carcinoma: the SANTORIN cohort study.
Noize P, Grelaud A, Bay JO, Chevreau C, Gross-Goupil M, Culine S, Ferrière JM, Moulin F, Robinson P, Balestra A, Lamarque S, Bernard MA, Lassalle R, Rouyer M, Droz-Perroteau C, Moore N, Fourrier-Réglat A, Ravaud A. Noize P, et al. Among authors: rouyer m. Pharmacoepidemiol Drug Saf. 2017 Dec;26(12):1561-1569. doi: 10.1002/pds.4228. Epub 2017 Jun 1. Pharmacoepidemiol Drug Saf. 2017. PMID: 28573786
Effectiveness of Cetuximab as First-Line Therapy for Patients With Wild-Type KRAS and Unresectable Metastatic Colorectal Cancer in Real-Life Practice: Results of the EREBUS Cohort.
Rouyer M, François E, Cunha AS, Monnereau A, Noize P, Robinson P, Droz-Perroteau C, Le Monies de Sagazan A, Jové J, Lassalle R, Moore N, Fourrier-Réglat A, Smith D; EREBUS Study Group. Rouyer M, et al. Clin Colorectal Cancer. 2018 Jun;17(2):129-139. doi: 10.1016/j.clcc.2018.01.007. Epub 2018 Jan 31. Clin Colorectal Cancer. 2018. PMID: 29523416
80 results